Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

<p>Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, […]</p>
<p>The post <a href="https://forextv.com/top-news/cidara-therapeutics-to-present-new-preclinical-data-on-novel-dual-acting-drug-fc-conjugates-at-esmo-immuno-oncology-annual-congress/">Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>